CASI Pharmaceuticals, Inc. (CASI) reported a third quarter net loss attributable to CASI of $4.6 million compared to a loss of $5.2 million, prior year. Net loss per share was $0.35 compared to a loss of $0.38. Total revenues declined to $8.8 million from $10.2 million, last year. Research and development expenses were $2.4 million, compared with $3.9 million, a year ago.
Wei-Wu He, CEO of CASI Pharmaceuticals, said: "The third quarter EVOMELA sales performance was impacted by the recent launch of an undifferentiated generic formulation of melphalan for injection product."
As of September 30, 2023, the company had cash, cash equivalents and short-term investments of $34.2 million.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.